

**Subject:** Single-dose Menveo® available for ASN providers beginning September 1

Adult Safety Net (ASN) program Responsible Entities (RE),

Vaccine manufacturer GlaxoSmithKline (GSK) is releasing a single-dose vial presentation of the Menveo® Meningococcal Conjugate vaccine (Groups A, C, Y and W-135), which does not require reconstitution.

| <b>Vaccine</b> | <b>NDC</b>    | <b>Presentation</b>       | <b>Age Indication</b> |
|----------------|---------------|---------------------------|-----------------------|
| Menveo®        | 58160-0827-30 | Single-dose vial, 10 pack | 10 through 55 years   |

ASN program providers may begin ordering the new single-dose vial presentation in the Vaccine Allocation and Ordering System (VAOS) beginning Friday, September 1, 2023.

Please contact [ASNInfo@dshs.texas.gov](mailto:ASNInfo@dshs.texas.gov) or [TXVaccineOrders@dshs.texas.gov](mailto:TXVaccineOrders@dshs.texas.gov) with questions.

Thank you for your continued participation in the ASN program.